EyePoint Pharmaceuticals Announces First Quarter 2025 Financial Results

Published on May 8, 2025
WATERTOWN, Mass.—EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company and a developer of therapeutics for patients with serious retinal diseases, has announced financial results for the first quarter ended March 31, 2025. The company reported total net revenue of $24.5 million compared with $11.7 million for the quarter ended March 31, 2024. Net product revenue was $0.7 million, consistent with the prior-year period.
Continue reading on website
Other news

Topcon announces dual launch of IDHea and Cascader Limited

May 7, 2025
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in health care, alongside Cascader Limited, which was created in partnership with Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology (IoO).

What do you say when your best friend asks for dry eye advice?

May 8, 2025
When her friend began experiencing dry eye symptoms while undergoing chemotherapy, Katherine Mastrota, OD, MS, FAAO, Dipl ABO, found herself in a unique position to provide specialized advice.